On January 8, 2014, PerkinElmer, Inc. ('PerkinElmer') entered into an unsecured revolving credit facility (the 'Credit Agreement') with PerkinElmer, Wallac Oy, and PerkinElmer Health Sciences, Inc. as Borrowers, JPMorgan Chase Bank, N.A. acting as Administrative Agent, and other lenders party thereto. Bank of America, N.A. and Barclays Bank PLC acted as Co-Syndication Agents, The Royal Bank of Scotland PLC, Citibank, N.A. and HSBC Bank USA, National Association acted as Co-Documentation Agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Bank PLC acted as Joint Bookrunners and Joint Lead Arrangers. The Credit Agreement provides for a $700.0 million committed unsecured revolving credit facility through January 8, 2019.

This Credit Agreement replaces the second amended and restated unsecured revolving credit agreement (the 'Prior Credit Agreement') dated as of December 16, 2011, as amended, among PerkinElmer, Wallac Oy and PerkinElmer Health Sciences, Inc. as Borrowers, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and the other lenders from time to time party thereto. The Prior Credit Agreement provided for a $700.0 million unsecured revolving credit facility through the fifth anniversary of the closing date. Borrowings made pursuant to the Credit Agreement will bear interest, payable quarterly or, if earlier, at the end of any interest period, at either (a) the base rate or (b) the Eurocurrency rate (a publicly published rate), in each case plus a percentage spread based on PerkinElmer's credit rating.